Effects of Iron and Brefeldin A on Release of Ferritin from Hepatoma Cells
| Treatment . | Dose . | Total Ferritin in Medium (μg) . | Inhibition by BFA (%) . | Total Albumin in Medium (μg) . | Inhibition by BFA (%) . |
|---|---|---|---|---|---|
| . | (μg Fe/mL) . | . | . | . | . |
| None (6) | 0 | 4.3 ± 0.6 | 192 ± 12 | ||
| Fe-NTA (3) | 10 | 8.5 ± 2.43-150 | 144 ± 43-150 | ||
| +BFA (3) | 10 | 3.6 ± 0.13-151 | 58 | 45 ± 53-151 | 69 |
| Fe-NTA (3) | 20 | 6.6 ± 0.73-150 | 135 ± 53-150 | ||
| +BFA (3) | 20 | 3.2 ± 0.13-151 | 52 | 45 ± 13-151 | 67 |
| Imferon (3) | 15 | 5.6 ± 0.63-150 | 208 ± 5 | ||
| +BFA (3) | 15 | 3.9 ± 0.13-151 | 31 | 87 ± 33-151 | 59 |
| Treatment . | Dose . | Total Ferritin in Medium (μg) . | Inhibition by BFA (%) . | Total Albumin in Medium (μg) . | Inhibition by BFA (%) . |
|---|---|---|---|---|---|
| . | (μg Fe/mL) . | . | . | . | . |
| None (6) | 0 | 4.3 ± 0.6 | 192 ± 12 | ||
| Fe-NTA (3) | 10 | 8.5 ± 2.43-150 | 144 ± 43-150 | ||
| +BFA (3) | 10 | 3.6 ± 0.13-151 | 58 | 45 ± 53-151 | 69 |
| Fe-NTA (3) | 20 | 6.6 ± 0.73-150 | 135 ± 53-150 | ||
| +BFA (3) | 20 | 3.2 ± 0.13-151 | 52 | 45 ± 13-151 | 67 |
| Imferon (3) | 15 | 5.6 ± 0.63-150 | 208 ± 5 | ||
| +BFA (3) | 15 | 3.9 ± 0.13-151 | 31 | 87 ± 33-151 | 59 |
Conditions were the same as described in Table 2, except that the data are given as micrograms of protein per flask and that treatments were with iron, in the form of a 1:1 molar Fe(III)-nitrilotriacetate complex (Fe-NTA) or iron dextran (Imferon), ± brefeldin A (BFA) (4 μg/mL). Values are means ± SD (for the number of flasks indicated in parentheses). There was no significant effect of any of the treatments on cell growth or viability, as determined by the amounts of cell protein per flask.
P < .05 to P < .001 for difference from controls.
Significant inhibition by BFA (P < .001).